Equity
Bristol-Myers Squibb·Balance Sheet Statement·8 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities and stockholders' equity | $94.6B | $93.7B | $92.6B | $92.4B | $94.7B | $96.9B | $90.0B | $86.5B |
| Additional paid-in capital | $45.8B | $45.9B | $46.0B | $46.0B | $46.1B | $46.3B | $46.4B | $46.4B |
| Treasury stock | $43.7B | $43.7B | $43.7B | $43.6B | $43.6B | $43.6B | $43.6B | $43.5B |
| Total stockholders' equity | $17.0B | $17.1B | $16.3B | $17.4B | $17.4B | $18.6B | $18.5B | $20.1B |
| Retained earnings | $16.1B | $16.1B | $14.9B | $16.1B | $16.2B | $17.1B | $16.9B | $18.3B |
| Accumulated other comprehensive income (loss) | -$1.5B | -$1.5B | -$1.2B | -$1.4B | -$1.6B | -$1.5B | -$1.5B | -$1.4B |
| Common stock | $292.0M | $292.0M | $292.0M | $292.0M | $292.0M | $292.0M | $292.0M | $292.0M |
| Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |